Destiny Pharma’s nasal gel formulation has good safety profile
Destiny Pharma’s XF-73 nasal gel formulation has been classified non-irritant, in the second Phase 1 study, which confirms the good safety profile.
Read more
Destiny Pharma
Positive data supports product opportunities for XF-73 in dermal infection indications
Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s
Read moreDestiny Pharma names new non-executive director
Destiny Pharm has consolidate its board with appointing Nick Rodgers as an independent Non-Executive Director with immediate effect.
Read more
FDA fast tracks Destiny Pharma’s candidate for prevention of infections like MRSA
FDA has fast tracked Destiny Pharma’s lead clinical candidate exeporfinium chloride (XF-73) for the prevention of post-surgical staphylococcal infections such
Read more
Destiny Pharma, China’s CMS Medical Venture ink deal for dealing with Destiny’s drug candidates in Asian region
Destiny Pharma said on Friday that its development and commercialisation collaboration agreement with CMS Medical Venture Investment Limited, a wholly
Read more
Destiny Pharma welcomes new CEO
Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.
Read more